Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

S100A7 (S100 calcium binding protein A7)

Written2010-04Jill I Murray, Martin J Boulanger
Department of Biochemistry, Microbiology, University of Victoria, Victoria, British Columbia V8W 3P6, Canada

(Note : for Links provided by Atlas : click)


HGNC (Hugo) S100A7
HGNC Alias symbS100A7c
HGNC Previous namePSOR1
HGNC Previous nameS100 calcium-binding protein A7 (psoriasin 1)
 S100 calcium binding protein A7 (psoriasin 1)
LocusID (NCBI) 6278
Atlas_Id 42194
Location 1q21.3  [Link to chromosome band 1q21]
Location_base_pair Starts at 153457744 and ends at 153460651 bp from pter ( according to GRCh38/hg38-Dec_2013)  [Mapping S100A7.png]
Local_order S100A7 is located on chromosome 1cen-q21 between D1Z5 and MUC1 (Borglum et al., 1995).
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)
Note S100A7 is also known as psoriasin, psoriasin 1, S100 calcium binding protein A7, S100-A7, S100A7c, and PSOR1.
S100A7, a member of the S100 family, was first identified as a protein upregulated in psoriasis (Madsen et al., 1991).


Note S100A7 is located on chromosome 1q21 within the epidermal differentiation complex.
  The S100A7 genomic organization includes 3 exons and 2 introns with exons 2 and 3 containing the protein encoding sequence (Semprini et al., 1999). The EF-hand domains are highlighted (Burgisser et al., 1995).
Description The S100A7 gene has 3 exons and 2 introns with a genomic structure similar to other S100 family members. Exon 1 encodes the 5' untranslated region while exons 2 and 3 contain the protein coding sequence. Exon 2 encodes the start codon and the non-canonical N-terminal EF-hand while exon 3 encodes the carboxyl-terminal EF-hand.
Transcription The S100A7 gene encodes for a single constitutively spliced transcript. An EST has been reported in which an alternative promoter is used to produce an identical S100A7 mRNA (See Ensembl, UCSC genome browser).
Pseudogene Five copies of S100A7 in the human genome have been reported including the closely related paralog S100A15 (also known as S100A7A) (Kulski et al., 2003; Wolf et al., 2003). Two of the five reported copies of S100A7, S100A7d (S100A7P1) and S100A7e (S100A7P2), are proposed to be non-coding pseudogenes (Kulski et al., 2003; Marenholz et al., 2006).


Note S100A7 is a member of the S100 family of calcium-binding signaling proteins. S100A7 has both intracellular and extracellular functions.
  A. S100A7 primary sequence highlighting the calcium- and zinc-binding residues and the EF-hand domains.
B. The 3D structure of zinc- and calcium-bound S100A7 dimer (2psr).
Description S100A7 is a small 11.4 kDa protein containing a C-terminal canonical calcium-binding EF-hand motif and an N-terminal non-canonical EF-hand motif which is characteristic of the S100 protein family. S100A7 forms a homodimer with one Ca2+ ion bound by the canonical EF-hand motif in each monomer and two Zn2+ ions located at the dimer interface (Brodersen et al., 1999). S100A7 monomers and putative higher order multimers have been observed in both psoriatic and healthy epidermis (Ruse et al., 2001).
Expression S100A7 is present at low levels in healthy skin, however it is highly upregulated in psoriatic epidermal keratinocytes (Madsen et al., 1991). E. Coli has been shown to induce S100A7 expression in keratinocytes (Gläser et al., 2005).
S100A7 expression is upregulated in several cancers including skin, breast, lung, head, neck, cervix, bladder and gastric cancer (for review see Emberley et al., 2004).
S100A7 expression is induced in MCF10 cells by stresses such as serum deprivation and cell confluency (Enerback et al., 2002).
S100A7 is repressed by BRCA1 in a c-myc dependent manner in HCC-BR116 cells (Kennedy et al., 2005). 17beta-estradiol treatment increased S100A7 expression in an estrogen receptor beta dependent manner in MCF-7 cells (Skliris et al., 2007). Epidermal Growth Factor induces S100A7 expression in MCF-7 and MDA-MB-468 cells (Paruchuri et al., 2008).
S100A7 expression is induced by proinflammatory cytokines in skin and breast cancer cells. S100A7 expression is enhanced in human keratinocytes by stimulation with the cytokine IL-22 in combination with IL-17 or IL-17F (Liang et al., 2006). Oncostatin-M was shown to induce S100A7 expression in human epidermal cell skin equivalents (Gazel et al., 2006). S100A7 expression is induced by the cytokines oncostatin-M and IL-6 in MCF-7, TD47 and MDA-MB-468 cell lines (West and Watson, 2010).
Localisation S100A7 is localized to the cytoplasm, nucleus, cell periphery and is also secreted from cells. In keratinocytes, S100A7 is observed in the cytoplasm when untreated and at the cell periphery upon stimulation with calcium (Ruse et al., 2003). S100A7 is expressed at low levels or is not detected in healthy breast cells. In breast cancer cells, however, S100A7 is observed in the nucleus and cytoplasm and is also secreted (Al-Haddad et al., 1999; Enerback et al., 2002).
Function S100A7 has been shown to function as a chemotactic factor for neutrophils and CD4+ T cells (Jinquan et al., 1996). S100A7 binds RAGE (receptor for advanced glycation end products) in a zinc-dependent manner and is proposed to mediate chemotaxis in a RAGE-dependent manner (Wolf et al., 2008). S100A7 present in skin functions as a Zn-dependent antimicrobial towards E.Coli (Glaser et al., 2005). S100A7 has also been shown to play an antibacterial role in wound healing (Lee and Eckert, 2007). S100A7 is a substrate for transglutaminase (Ruse et al., 2001).
S100A7 interacts, co-purifies and colocalizes in the cytoplasm with epidermal-type fatty acid-binding protein (E-FABP), a protein which is also upregulated in psoriasis (Hagens et al., 1999; Ruse et al., 2003). S100A7 has been shown to interact with RanBPM by yeast two-hybrid and co-immunoprecipitation studies in breast cancer cells (Emberley et al., 2002). S100A7 has been shown to interact with the multifunctional signalling protein, Jab1, yeast two-hybrid and co-immunoprecipitation studies in breast cancer cells (Emberley et al., 2003). The Jab1-S100A7 interaction and downstream effects were disrupted by mutation of a Jab1-binding site (Emberley et al., 2003; West et al., 2009).
Homology S100A7 is a member of the S100 family of vertebrate proteins. Among the S100 family, S100A7 is the most divergent (Burgisser et al., 1995) with the exception of a recently identified paralog S100A715 (or S100A7A), with which it shares 93% similarity (Wolf et al., 2003). A bovine ortholog to S100A7, Bosd3 (Virtanen, 2006) and equine ortholog (Leeb et al., 2005) have also been reported. The mouse S100A7, which has 40% similarity (Webb et al., 2005), has been assigned the designation mouse S100A15 (Wolf et al., 2006).


Note An allergy associated polymorphism of S100A7 (rs3014837) has been reported (Bryborn et al., 2008).

Implicated in

Entity Psoriasis and other skin diseases
Note S100A7 is associated with inflammation in several skin diseases (Algermissen et al., 1996). S100A7 was originally identified as a protein secreted from psoriatic skin (Madsen et al., 1991). S100A7 is also overexpressed in skin lesions of patients with lichen sclerosus (Gambichler et al., 2009), acne inversa (Schlapbach et al., 2009), and middle ear cholesteatoma (Kim et al., 2009).
Entity Non-melanoma skin cancer
Note S100A7 may play a role in the progression of skin cancer. S100A7 expression is not observed in healthy epidermis. When S100A7 levels were studied by immunohistochemistry in squamous cell carcinoma skin lesions, higher levels of expression were found in pre-invasive squamous cell carcinoma in situ compared to invasive squamous cell carcinoma (Alowami et al., 2003). In a separate study, S100A7 mRNA levels, determined by real-time PCR, were upregulated in pre-cancerous skin lesions and epithelial skin tumours including basal cell carcinoma and squamous cell carcinoma (Moubayed et al., 2007).
Entity Melanoma
Note S100A7 protein was observed at higher levels in the urine of melanoma patients compared to healthy controls (Brouard et al., 2002), although S100A7 was not detected in melanoma cells (Petersson et al., 2009).
Entity and breast cancer
Note S100A7 was first associated with primary breast cancer (Moog-Lutz et al., 1995). Later studies identified S100A7 as one of the most highly expressed genes in DCIS, a key stage before the transition to invasive breast cancer (Leygue et al., 1996; Enerback et al., 2002). When S100A7 is expressed in later stages of breast cancer it is associated with the agressive estrogen-negative tumors and poor prognosis (Al-Haddad et al., 1999; Emberley et al., 2004). In vivo mouse model studies have shown that S100A7 promotes tumorigenesis (Emberley et al., 2003; Krop et al., 2005). Several of the tumorigenic effects of S100A7, including upregulation of NF-kappaB, PI3K-Akt, and AP-1 as well as promotion of cell survival, are mediated by the interaction of S100A7 with Jab1 (Emberley et al., 2003; Emberley et al., 2005).
Entity Epithelial ovarian cancer
Note S1007 mRNA and protein levels are upregulated in epithelial ovarian carcinoma tissue compared to normal and benign ovary tissue (Gagnon et al., 2008). Autoantibodies to S100A7 were detected at higher levels in the plasma of early and late-stage ovarian cancer patients compared to healthy controls (Gagnon et al., 2008). S100A7 autoantibodies may be useful as a biomarker for epithelial ovarian cancer (for review see Piura and Piura, 2009).
Entity Lung squamous cell carcinoma
Note S100A7 is associated with non-small lung squamous cell carcinoma metastasis to the brain (Zhang et al., 2007). Proteomic studies identified S100A7 as a protein upregulated in a brain metastasis lung squamous cell carcinoma cell line and S100A7 overexpression was confirmed in brain metastasis tissues (Zhang et al., 2007).
Entity Bladder squamous cell carcinoma
Note S100A7 was detected in bladder squamous cell carcinoma tumors and also in the urine of patients with bladder squamous cell carcinoma (Celis et al., 1996; Ostergaard et al., 1997). As a result, S100A7 has been proposed to be a potential biomarker for bladder squamous cell carcinoma (Celis et al., 1996; Ostergaard et al., 1997; Ostergaard et al., 1999).
Entity Oral squamous cell carcinoma
Note S100A7 is associated with oral squamous cell carcinoma (Zhou et al., 2008; Kesting et al., 2009). RT-PCR and immunofluorescence studies showed that S100A7 mRNA and protein levels respectively are up-regulated in oral squamous cell carcinoma tissues compared to normal oral tissues (Kesting et al., 2009).
Entity Head-and-neck squamous cell carcinoma
Note S100A7 is a highly upregulated biomarker in head-and-neck squamous cell carcinomas (Ralhan et al., 2008).
Entity Gastric cancer
Note SAGE (serial analysis of gene expression) studies identified S100A7 as one of the top twenty genes upregulated in gastric cancer (El-Rifai et al., 2002). Further mining of publicly available SAGE, virtual Northern Blot, and microarray data confirmed the association of S100 proteins such as S100A7 with gastric cancer (Liu et al., 2008).
Entity Chronic rhinosinusitis
Note Chronic rhinosinusitis (CRS) is characterized by a persistant inflammation of the nasal mucosa. It has been proposed that the antibacterial function of S100A7 play a role in protecting against the environmental factors that contribute to chronic rinosinusitis (for review see Tieu et al., 2009). Reduced levels of S100A7 were detected in the nasal lavage fluid of patients with allergic rhinitis when compared to controls (Bryborn et al., 2005). A polymorphism (RS3014837) has been linked with allergic individuals in Sweden (Bryborn et al., 2008).
Entity Systemic sclerosis (SSc)
Note S100A7 is upregulated in the saliva of patients with systemic sclerosis when compared to healthy individuals and has been proposed as a potential biomarker for systemic sclerosis with pulmonary involvement (Giusti et al., 2007; Baldini et al., 2008).
Entity Alzheimer's disease
Note A recent study has suggested that S100A7 is a potential biomarker for Alzheimer's disease. Increased levels of S100A7 were detected in the cerebralspinal fluid and brain of patients with Alzheimer's disease (Qin et al., 2009).


Psoriasin (S100A7) expression and invasive breast cancer.
Al-Haddad S, Zhang Z, Leygue E, Snell L, Huang A, Niu Y, Hiller-Hitchcock T, Hole K, Murphy LC, Watson PH.
Am J Pathol. 1999 Dec;155(6):2057-66.
PMID 10595935
Differential expression of CRABP II, psoriasin and cytokeratin 1 mRNA in human skin diseases.
Algermissen B, Sitzmann J, LeMotte P, Czarnetzki B.
Arch Dermatol Res. 1996 Jul;288(8):426-30.
PMID 8844119
Psoriasin (S100A7) expression is altered during skin tumorigenesis.
Alowami S, Qing G, Emberley E, Snell L, Watson PH.
BMC Dermatol. 2003 Feb 24;3:1. Epub 2003 Feb 24.
PMID 12600274
Association of psoriasin (S100A7) with clinical manifestations of systemic sclerosis: is its presence in whole saliva a potential predictor of pulmonary involvement?
Baldini C, Giusti L, Bazzichi L, Ciregia F, Giannaccini G, Giacomelli C, Doveri M, Del Rosso M, Bombardieri S, Lucacchini A.
J Rheumatol. 2008 Sep;35(9):1820-4. Epub 2008 Jul 15.
PMID 18634149
Refined mapping of the psoriasin gene S100A7 to chromosome 1cen-q21.
Borglum AD, Flint T, Madsen P, Celis JE, Kruse TA.
Hum Genet. 1995 Nov;96(5):592-6.
PMID 8530009
Zinc-binding site of an S100 protein revealed. Two crystal structures of Ca2+-bound human psoriasin (S100A7) in the Zn2+-loaded and Zn2+-free states.
Brodersen DE, Nyborg J, Kjeldgaard M.
Biochemistry. 1999 Feb 9;38(6):1695-704.
PMID 10026247
Urinary excretion of epidermal-type fatty acid-binding protein and S100A7 protein in patients with cutaneous melanoma.
Brouard MC, Saurat JH, Ghanem G, Siegenthaler G.
Melanoma Res. 2002 Dec;12(6):627-31.
PMID 12459653
Psoriasin, one of several new proteins identified in nasal lavage fluid from allergic and non-allergic individuals using 2-dimensional gel electrophoresis and mass spectrometry.
Bryborn M, Adner M, Cardell LO.
Respir Res. 2005 Oct 19;6:118.
PMID 16236163
Comprehensive evaluation of genetic variation in S100A7 suggests an association with the occurrence of allergic rhinitis.
Bryborn M, Hallden C, Sall T, Adner M, Cardell LO.
Respir Res. 2008 Mar 28;9:29.
PMID 18373864
Amino acid sequence analysis of human S100A7 (psoriasin) by tandem mass spectrometry.
Burgisser DM, Siegenthaler G, Kuster T, Hellman U, Hunziker P, Birchler N, Heizmann CW.
Biochem Biophys Res Commun. 1995 Dec 5;217(1):257-63.
PMID 8526920
Bladder squamous cell carcinomas express psoriasin and externalize it to the urine.
Celis JE, Rasmussen HH, Vorum H, Madsen P, Honore B, Wolf H, Orntoft TF.
J Urol. 1996 Jun;155(6):2105-12.
PMID 8618345
Gastric cancers overexpress S100A calcium-binding proteins.
El-Rifai W, Moskaluk CA, Abdrabbo MK, Harper J, Yoshida C, Riggins GJ, Frierson HF Jr, Powell SM.
Cancer Res. 2002 Dec 1;62(23):6823-6.
PMID 12460893
The S100A7-c-Jun activation domain binding protein 1 pathway enhances prosurvival pathways in breast cancer.
Emberley ED, Niu Y, Curtis L, Troup S, Mandal SK, Myers JN, Gibson SB, Murphy LC, Watson PH.
Cancer Res. 2005 Jul 1;65(13):5696-702.
PMID 15994944
Psoriasin expression in mammary epithelial cells in vitro and in vivo.
Enerback C, Porter DA, Seth P, Sgroi D, Gaudet J, Weremowicz S, Morton CC, Schnitt S, Pitts RL, Stampl J, Barnhart K, Polyak K.
Cancer Res. 2002 Jan 1;62(1):43-7.
PMID 11782356
Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients.
Gagnon A, Kim JH, Schorge JO, Ye B, Liu B, Hasselblatt K, Welch WR, Bandera CA, Mok SC.
Clin Cancer Res. 2008 Feb 1;14(3):764-71.
PMID 18245537
Significant upregulation of antimicrobial peptides and proteins in lichen sclerosus.
Gambichler T, Skrygan M, Tigges C, Kobus S, Glaser R, Kreuter A.
Br J Dermatol. 2009 Nov;161(5):1136-42. Epub 2009 Apr 30.
PMID 19558556
A characteristic subset of psoriasis-associated genes is induced by oncostatin-M in reconstituted epidermis.
Gazel A, Rosdy M, Bertino B, Tornier C, Sahuc F, Blumenberg M.
J Invest Dermatol. 2006 Dec;126(12):2647-57. Epub 2006 Aug 17.
PMID 16917497
Specific proteins identified in whole saliva from patients with diffuse systemic sclerosis.
Giusti L, Bazzichi L, Baldini C, Ciregia F, Mascia G, Giannaccini G, Del Rosso M, Bombardieri S, Lucacchini A.
J Rheumatol. 2007 Oct;34(10):2063-9. Epub 2007 Aug 15.
PMID 17722226
Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infection.
Glaser R, Harder J, Lange H, Bartels J, Christophers E, Schroder JM.
Nat Immunol. 2005 Jan;6(1):57-64. Epub 2004 Nov 28.
PMID 15568027
Calcium-binding protein S100A7 and epidermal-type fatty acid-binding protein are associated in the cytosol of human keratinocytes.
Hagens G, Masouye I, Augsburger E, Hotz R, Saurat JH, Siegenthaler G.
Biochem J. 1999 Apr 15;339 ( Pt 2):419-27.
PMID 10191275
Psoriasin: a novel chemotactic protein.
Jinquan T, Vorum H, Larsen CG, Madsen P, Rasmussen HH, Gesser B, Etzerodt M, Honore B, Celis JE, Thestrup-Pedersen K.
J Invest Dermatol. 1996 Jul;107(1):5-10.
PMID 8752830
BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene.
Kennedy RD, Gorski JJ, Quinn JE, Stewart GE, James CR, Moore S, Mulligan K, Emberley ED, Lioe TF, Morrison PJ, Mullan PB, Reid G, Johnston PG, Watson PH, Harkin DP.
Cancer Res. 2005 Nov 15;65(22):10265-72.
PMID 16288014
Psoriasin (S100A7) up-regulation in oral squamous cell carcinoma and its relation to clinicopathologic features.
Kesting MR, Sudhoff H, Hasler RJ, Nieberler M, Pautke C, Wolff KD, Wagenpfeil S, Al-Benna S, Jacobsen F, Steinstraesser L.
Oral Oncol. 2009 Aug;45(8):731-6. Epub 2009 Jan 14.
PMID 19147391
Psoriasin (S100A7), an antimicrobial peptide, is increased in human middle ear cholesteatoma.
Kim KH, Cho JG, Song JJ, Woo JS, Lee HM, Jung HH, Hwang SJ, Chae S.
Acta Otolaryngol. 2009 Aug 25:1-5. (Epub ahead of print)
PMID 19707901
A putative role for psoriasin in breast tumor progression.
Krop I, Marz A, Carlsson H, Li X, Bloushtain-Qimron N, Hu M, Gelman R, Sabel MS, Schnitt S, Ramaswamy S, Kleer CG, Enerback C, Polyak K.
Cancer Res. 2005 Dec 15;65(24):11326-34.
PMID 16357139
Genomic and phylogenetic analysis of the S100A7 (Psoriasin) gene duplications within the region of the S100 gene cluster on human chromosome 1q21.
Kulski JK, Lim CP, Dunn DS, Bellgard M.
J Mol Evol. 2003 Apr;56(4):397-406.
PMID 12664160
S100A7 (Psoriasin)--mechanism of antibacterial action in wounds.
Lee KC, Eckert RL.
J Invest Dermatol. 2007 Apr;127(4):945-57. Epub 2006 Dec 7.
PMID 17159909
Assignment of the equine S100A7 gene (psoriasin 1) to chromosome 5p12-->p13 by fluorescence in situ hybridization and radiation hybrid mapping.
Leeb T, Bruhn O, Philipp U, Kuiper H, Regenhard P, Paul S, Distl O, Chowdhary BP, Kalm E, Looft C.
Cytogenet Genome Res. 2005;109(4):533.
PMID 15906470
Differential expression of psoriasin messenger RNA between in situ and invasive human breast carcinoma.
Leygue E, Snell L, Hiller T, Dotzlaw H, Hole K, Murphy LC, Watson PH.
Cancer Res. 1996 Oct 15;56(20):4606-9.
PMID 8840971
Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides.
Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, Fouser LA.
J Exp Med. 2006 Oct 2;203(10):2271-9. Epub 2006 Sep 18.
PMID 16982811
In silico analysis and verification of S100 gene expression in gastric cancer.
Liu J, Li X, Dong GL, Zhang HW, Chen DL, Du JJ, Zheng JY, Li JP, Wang WZ.
BMC Cancer. 2008 Sep 16;8:261.
PMID 18793447
Molecular cloning, occurrence, and expression of a novel partially secreted protein "psoriasin" that is highly up-regulated in psoriatic skin.
Madsen P, Rasmussen HH, Leffers H, Honore B, Dejgaard K, Olsen E, Kiil J, Walbum E, Andersen AH, Basse B, Lauridsen JB, Ratz GP, Celis A, Vandekerckhove J, Celis JE.
J Invest Dermatol. 1991 Oct;97(4):701-12.
PMID 1940442
An update of the S100 nomenclature.
Marenholz I, Lovering RC, Heizmann CW.
Biochim Biophys Acta. 2006 Nov;1763(11):1282-3. Epub 2006 Jul 26.
PMID 16938360
Comparative expression of the psoriasin (S100A7) and S100C genes in breast carcinoma and co-localization to human chromosome 1q21-q22.
Moog-Lutz C, Bouillet P, Regnier CH, Tomasetto C, Mattei MG, Chenard MP, Anglard P, Rio MC, Basset P.
Int J Cancer. 1995 Oct 9;63(2):297-303.
PMID 7591220
Psoriasin (S100A7) is significantly up-regulated in human epithelial skin tumours.
Moubayed N, Weichenthal M, Harder J, Wandel E, Sticherling M, Glaser R.
J Cancer Res Clin Oncol. 2007 Apr;133(4):253-61. Epub 2006 Nov 29.
PMID 17136347
Proteome profiling of bladder squamous cell carcinomas: identification of markers that define their degree of differentiation.
Ostergaard M, Rasmussen HH, Nielsen HV, Vorum H, Orntoft TF, Wolf H, Celis JE.
Cancer Res. 1997 Sep 15;57(18):4111-7.
PMID 9307301
S100A7-downregulation inhibits epidermal growth factor-induced signaling in breast cancer cells and blocks osteoclast formation.
Paruchuri V, Prasad A, McHugh K, Bhat HK, Polyak K, Ganju RK.
PLoS One. 2008 Mar 5;3(3):e1741.
PMID 18320059
Expression patterns of S100 proteins in melanocytes and melanocytic lesions.
Petersson S, Shubbar E, Enerback L, Enerback C.
Melanoma Res. 2009 Aug;19(4):215-25.
PMID 19521263
Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma.
Piura B, Piura E.
J Oncol. 2009;2009:581939. Epub 2010 Jan 17. (REVIEW)
PMID 20145720
S100A7, a novel Alzheimer's disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10.
Qin W, Ho L, Wang J, Peskind E, Pasinetti GM.
PLoS One. 2009;4(1):e4183. Epub 2009 Jan 13.
PMID 19159013
Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry.
Ralhan R, Desouza LV, Matta A, Chandra Tripathi S, Ghanny S, Datta Gupta S, Bahadur S, Siu KW.
Mol Cell Proteomics. 2008 Jun;7(6):1162-73. Epub 2008 Mar 13.
PMID 18339795
S100A7 (psoriasin) interacts with epidermal fatty acid binding protein and localizes in focal adhesion-like structures in cultured keratinocytes.
Ruse M, Broome AM, Eckert RL.
J Invest Dermatol. 2003 Jul;121(1):132-41.
PMID 12839573
S100A7, S100A10, and S100A11 are transglutaminase substrates.
Ruse M, Lambert A, Robinson N, Ryan D, Shon KJ, Eckert RL.
Biochemistry. 2001 Mar 13;40(10):3167-73.
PMID 11258932
Human beta-defensin-2 and psoriasin are overexpressed in lesions of acne inversa.
Schlapbach C, Yawalkar N, Hunger RE.
J Am Acad Dermatol. 2009 Jul;61(1):58-65. Epub 2009 Feb 26.
PMID 19249126
Genomic structure, promoter characterisation and mutational analysis of the S100A7 gene: exclusion of a candidate for familial psoriasis susceptibility.
Semprini S, Capon F, Bovolenta S, Bruscia E, Pizzuti A, Fabrizi G, Schietroma C, Zambruno G, Dallapiccola B, Novelli G.
Hum Genet. 1999 Feb;104(2):130-4.
PMID 10190323
Estrogen receptor-beta regulates psoriasin (S100A7) in human breast cancer.
Skliris GP, Lewis A, Emberley E, Peng B, Weebadda WK, Kemp A, Davie JR, Shiu RP, Watson PH, Murphy LC.
Breast Cancer Res Treat. 2007 Jul;104(1):75-85. Epub 2006 Sep 29.
PMID 17009105
Alterations in epithelial barrier function and host defense responses in chronic rhinosinusitis.
Tieu DD, Kern RC, Schleimer RP.
J Allergy Clin Immunol. 2009 Jul;124(1):37-42. (REVIEW)
PMID 19560577
Psoriasin and its allergenic bovine homolog Bos d 3.
Virtanen T.
Cell Mol Life Sci. 2006 May;63(10):1091-4. (REVIEW)
PMID 16612562
Expression analysis of the mouse S100A7/psoriasin gene in skin inflammation and mammary tumorigenesis.
Webb M, Emberley ED, Lizardo M, Alowami S, Qing G, Alfia'ar A, Snell-Curtis LJ, Niu Y, Civetta A, Myal Y, Shiu R, Murphy LC, Watson PH.
BMC Cancer. 2005 Feb 17;5:17.
PMID 15717926
Structural and functional characterization of a triple mutant form of S100A7 defective for Jab1 binding.
West NR, Farnell B, Murray JI, Hof F, Watson PH, Boulanger MJ.
Protein Sci. 2009 Dec;18(12):2615-23.
PMID 19844956
S100A7 (psoriasin) is induced by the proinflammatory cytokines oncostatin-M and interleukin-6 in human breast cancer.
West NR, Watson PH.
Oncogene. 2010 Apr 8;29(14):2083-92. Epub 2010 Jan 18.
PMID 20101226
Chemotactic activity of S100A7 (Psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15.
Wolf R, Howard OM, Dong HF, Voscopoulos C, Boeshans K, Winston J, Divi R, Gunsior M, Goldsmith P, Ahvazi B, Chavakis T, Oppenheim JJ, Yuspa SH.
J Immunol. 2008 Jul 15;181(2):1499-506.
PMID 18606705
Molecular cloning and characterization of alternatively spliced mRNA isoforms from psoriatic skin encoding a novel member of the S100 family.
Wolf R, Mirmohammadsadegh A, Walz M, Lysa B, Tartler U, Remus R, Hengge U, Michel G, Ruzicka T.
FASEB J. 2003 Oct;17(13):1969-71. Epub 2003 Aug 15.
PMID 12923069
The mouse S100A15 ortholog parallels genomic organization, structure, gene expression, and protein-processing pattern of the human S100A7/A15 subfamily during epidermal maturation.
Wolf R, Voscopoulos CJ, FitzGerald PC, Goldsmith P, Cataisson C, Gunsior M, Walz M, Ruzicka T, Yuspa SH.
J Invest Dermatol. 2006 Jul;126(7):1600-8. Epub 2006 Mar 9.
PMID 16528363
Identification and validation of S100A7 associated with lung squamous cell carcinoma metastasis to brain.
Zhang H, Wang Y, Chen Y, Sun S, Li N, Lv D, Liu C, Huang L, He D, Xiao X.
Lung Cancer. 2007 Jul;57(1):37-45. Epub 2007 Apr 5.
PMID 17418446
Reciprocal negative regulation between S100A7/psoriasin and beta-catenin signaling plays an important role in tumor progression of squamous cell carcinoma of oral cavity.
Zhou G, Xie TX, Zhao M, Jasser SA, Younes MN, Sano D, Lin J, Kupferman ME, Santillan AA, Patel V, Gutkind JS, Ei-Naggar AK, Emberley ED, Watson PH, Matsuzawa SI, Reed JC, Myers JN.
Oncogene. 2008 Jun 5;27(25):3527-38. Epub 2008 Jan 28.
PMID 18223693


This paper should be referenced as such :
Murray, JI ; Boulanger, MJ
S100A7 (S100 calcium binding protein A7)
Atlas Genet Cytogenet Oncol Haematol. 2011;15(1):59-64.
Free journal version : [ pdf ]   [ DOI ]

External links


HGNC (Hugo)S100A7   10497
Entrez_Gene (NCBI)S100A7    S100 calcium binding protein A7
AliasesPSOR1; S100A7c
GeneCards (Weizmann)S100A7
Ensembl hg19 (Hinxton)ENSG00000143556 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000143556 [Gene_View]  ENSG00000143556 [Sequence]  chr1:153457744-153460651 [Contig_View]  S100A7 [Vega]
ICGC DataPortalENSG00000143556
TCGA cBioPortalS100A7
AceView (NCBI)S100A7
Genatlas (Paris)S100A7
SOURCE (Princeton)S100A7
Genetics Home Reference (NIH)S100A7
Genomic and cartography
GoldenPath hg38 (UCSC)S100A7  -     chr1:153457744-153460651 -  1q21.3   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)S100A7  -     1q21.3   [Description]    (hg19-Feb_2009)
GoldenPathS100A7 - 1q21.3 [CytoView hg19]  S100A7 - 1q21.3 [CytoView hg38]
Genome Data Viewer NCBIS100A7 [Mapview hg19]  
Gene and transcription
Genbank (Entrez)AW238300 BC034687 BF090388 BX476368 CR542164
RefSeq transcript (Entrez)NM_002963
Consensus coding sequences : CCDS (NCBI)S100A7
Gene ExpressionS100A7 [ NCBI-GEO ]   S100A7 [ EBI - ARRAY_EXPRESS ]   S100A7 [ SEEK ]   S100A7 [ MEM ]
Gene Expression Viewer (FireBrowse)S100A7 [ Firebrowse - Broad ]
GenevisibleExpression of S100A7 in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)6278
GTEX Portal (Tissue expression)S100A7
Human Protein AtlasENSG00000143556-S100A7 [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtP31151   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtP31151  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProP31151
Domaine pattern : Prosite (Expaxy)EF_HAND_1 (PS00018)    EF_HAND_2 (PS50222)    S100_CABP (PS00303)   
Domains : Interpro (EBI)EF-hand-dom_pair    EF_Hand_1_Ca_BS    EF_hand_dom    S-100_dom    S100/CaBP-9k_CS    S100_Ca-bd_sub    S100A7   
Domain families : Pfam (Sanger)S_100 (PF01023)   
Domain families : Pfam (NCBI)pfam01023   
Domain families : Smart (EMBL)S_100 (SM01394)  
Conserved Domain (NCBI)S100A7
PDB (RSDB)1PSR    2PSR    2WND    2WOR    2WOS    3PSR    4AQJ   
PDB Europe1PSR    2PSR    2WND    2WOR    2WOS    3PSR    4AQJ   
PDB (PDBSum)1PSR    2PSR    2WND    2WOR    2WOS    3PSR    4AQJ   
PDB (IMB)1PSR    2PSR    2WND    2WOR    2WOS    3PSR    4AQJ   
Structural Biology KnowledgeBase1PSR    2PSR    2WND    2WOR    2WOS    3PSR    4AQJ   
SCOP (Structural Classification of Proteins)1PSR    2PSR    2WND    2WOR    2WOS    3PSR    4AQJ   
CATH (Classification of proteins structures)1PSR    2PSR    2WND    2WOR    2WOS    3PSR    4AQJ   
AlphaFold pdb e-kbP31151   
Human Protein Atlas [tissue]ENSG00000143556-S100A7 [tissue]
Protein Interaction databases
IntAct (EBI)P31151
Ontologies - Pathways
Ontology : AmiGOresponse to reactive oxygen species  angiogenesis  calcium ion binding  calcium ion binding  protein binding  extracellular region  extracellular region  extracellular space  extracellular space  nucleus  cytoplasm  cytoplasm  endoplasmic reticulum  cytosol  focal adhesion  zinc ion binding  zinc ion binding  epidermis development  positive regulation of T cell chemotaxis  antimicrobial humoral response  keratinocyte differentiation  response to lipopolysaccharide  azurophil granule lumen  neutrophil degranulation  innate immune response  calcium-dependent protein binding  RAGE receptor binding  defense response to Gram-negative bacterium  sequestering of metal ion  antimicrobial humoral immune response mediated by antimicrobial peptide  collagen-containing extracellular matrix  positive regulation of ERK1 and ERK2 cascade  positive regulation of granulocyte chemotaxis  positive regulation of monocyte chemotaxis  
Ontology : EGO-EBIresponse to reactive oxygen species  angiogenesis  calcium ion binding  calcium ion binding  protein binding  extracellular region  extracellular region  extracellular space  extracellular space  nucleus  cytoplasm  cytoplasm  endoplasmic reticulum  cytosol  focal adhesion  zinc ion binding  zinc ion binding  epidermis development  positive regulation of T cell chemotaxis  antimicrobial humoral response  keratinocyte differentiation  response to lipopolysaccharide  azurophil granule lumen  neutrophil degranulation  innate immune response  calcium-dependent protein binding  RAGE receptor binding  defense response to Gram-negative bacterium  sequestering of metal ion  antimicrobial humoral immune response mediated by antimicrobial peptide  collagen-containing extracellular matrix  positive regulation of ERK1 and ERK2 cascade  positive regulation of granulocyte chemotaxis  positive regulation of monocyte chemotaxis  
REACTOMEP31151 [protein]
REACTOME PathwaysR-HSA-6799990 [pathway]   
NDEx NetworkS100A7
Atlas of Cancer Signalling NetworkS100A7
Wikipedia pathwaysS100A7
Orthology - Evolution
GeneTree (enSembl)ENSG00000143556
Phylogenetic Trees/Animal Genes : TreeFamS100A7
Homologs : HomoloGeneS100A7
Homology/Alignments : Family Browser (UCSC)S100A7
Gene fusions - Rearrangements
Fusion : QuiverS100A7
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerS100A7 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)S100A7
Exome Variant ServerS100A7
GNOMAD BrowserENSG00000143556
Varsome BrowserS100A7
ACMGS100A7 variants
Genomic Variants (DGV)S100A7 [DGVbeta]
DECIPHERS100A7 [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisS100A7 
ICGC Data PortalS100A7 
TCGA Data PortalS100A7 
Broad Tumor PortalS100A7
OASIS PortalS100A7 [ Somatic mutations - Copy number]
Cancer Gene: CensusS100A7 
Somatic Mutations in Cancer : COSMICS100A7  [overview]  [genome browser]  [tissue]  [distribution]  
Somatic Mutations in Cancer : COSMIC3DS100A7
Mutations and Diseases : HGMDS100A7
LOVD (Leiden Open Variation Database)[gene] [transcripts] [variants]
DgiDB (Drug Gene Interaction Database)S100A7
DoCM (Curated mutations)S100A7
CIViC (Clinical Interpretations of Variants in Cancer)S100A7
NCG (London)S100A7
Impact of mutations[PolyPhen2] [Provean] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Genetic Testing Registry S100A7
NextProtP31151 [Medical]
Target ValidationS100A7
Huge Navigator S100A7 [HugePedia]
Clinical trials, drugs, therapy
Protein Interactions : CTDS100A7
Pharm GKB GenePA34909
Clinical trialS100A7
canSAR (ICR)S100A7
DataMed IndexS100A7
PubMed174 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Oct 8 21:27:28 CEST 2021

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us